Purpose: To develop a fully automated procedure for multicriterial volumetric modulated arc therapy (VMAT) treatment planning (autoVMAT) for stage III/IV non-small cell lung cancer (NSCLC) patients treated with curative intent. Materials and methods: After configuring the developed autoVMAT system for NSCLC, autoVMAT plans were compared with manually generated clinically delivered intensity-modulated radiotherapy (IMRT) plans for 41 patients. AutoVMAT plans were also compared to manually generated VMAT plans in the absence of time pressure. For 16 patients with reduced planning target volume (PTV) dose prescription in the clinical IMRT plan (to avoid violation of organs at risk tolerances), the potential for dose escalation with autoVMAT was explored. Results: Two physicians evaluated 35/41 autoVMAT plans (85%) as clinically acceptable. Compared to the manually generated IMRT plans, autoVMAT plans showed statistically significant improved PTV coverage (V95%increased by 1.1% ± 1.1%), higher dose conformity (R50 reduced by 12.2% ± 12.7%), and reduced mean lung, heart, and esophagus doses (reductions of 0.9 Gy ± 1.0 Gy, 1.5 Gy ± 1.8 Gy, 3.6 Gy ± 2.8 Gy, respectively, all p < 0.001). To render the six remaining autoVMAT plans clinically acceptable, a dosimetrist needed less than 10 min hands-on time for fine-tuning. AutoVMAT plans were also considered equivalent or better than manually optimized VMAT plans. For 6/16 patients, autoVMAT allowed tumor dose escalation of 5–10 Gy. Conclusion: Clinically deliverable, high-quality autoVMAT plans can be generated fully automatically for the vast majority of advanced-stage NSCLC patients. For a subset of patients, autoVMAT allowed for tumor dose escalation.

Fully automated VMAT treatment planning for advanced-stage NSCLC patients / Della Gala, G.; Dirkx, M.L.P.; Hoekstra, N.; Fransen, D.; Lanconelli, N .; Pol, van de M.; Heijmen, B.J.M.; Petit, S.F.. - In: STRAHLENTHERAPIE UND ONKOLOGIE. - ISSN 0179-7158. - STAMPA. - 193:5(2017), pp. 402-409. [10.1007/s00066-017-1121-1]

Fully automated VMAT treatment planning for advanced-stage NSCLC patients

DELLA GALA, GIUSEPPE;LANCONELLI, NICO;
2017

Abstract

Purpose: To develop a fully automated procedure for multicriterial volumetric modulated arc therapy (VMAT) treatment planning (autoVMAT) for stage III/IV non-small cell lung cancer (NSCLC) patients treated with curative intent. Materials and methods: After configuring the developed autoVMAT system for NSCLC, autoVMAT plans were compared with manually generated clinically delivered intensity-modulated radiotherapy (IMRT) plans for 41 patients. AutoVMAT plans were also compared to manually generated VMAT plans in the absence of time pressure. For 16 patients with reduced planning target volume (PTV) dose prescription in the clinical IMRT plan (to avoid violation of organs at risk tolerances), the potential for dose escalation with autoVMAT was explored. Results: Two physicians evaluated 35/41 autoVMAT plans (85%) as clinically acceptable. Compared to the manually generated IMRT plans, autoVMAT plans showed statistically significant improved PTV coverage (V95%increased by 1.1% ± 1.1%), higher dose conformity (R50 reduced by 12.2% ± 12.7%), and reduced mean lung, heart, and esophagus doses (reductions of 0.9 Gy ± 1.0 Gy, 1.5 Gy ± 1.8 Gy, 3.6 Gy ± 2.8 Gy, respectively, all p < 0.001). To render the six remaining autoVMAT plans clinically acceptable, a dosimetrist needed less than 10 min hands-on time for fine-tuning. AutoVMAT plans were also considered equivalent or better than manually optimized VMAT plans. For 6/16 patients, autoVMAT allowed tumor dose escalation of 5–10 Gy. Conclusion: Clinically deliverable, high-quality autoVMAT plans can be generated fully automatically for the vast majority of advanced-stage NSCLC patients. For a subset of patients, autoVMAT allowed for tumor dose escalation.
2017
Fully automated VMAT treatment planning for advanced-stage NSCLC patients / Della Gala, G.; Dirkx, M.L.P.; Hoekstra, N.; Fransen, D.; Lanconelli, N .; Pol, van de M.; Heijmen, B.J.M.; Petit, S.F.. - In: STRAHLENTHERAPIE UND ONKOLOGIE. - ISSN 0179-7158. - STAMPA. - 193:5(2017), pp. 402-409. [10.1007/s00066-017-1121-1]
Della Gala, G.; Dirkx, M.L.P.; Hoekstra, N.; Fransen, D.; Lanconelli, N .; Pol, van de M.; Heijmen, B.J.M.; Petit, S.F.
File in questo prodotto:
File Dimensione Formato  
DellaGala2017_Article_FullyAutomatedVMATTreatmentPla.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 414.67 kB
Formato Adobe PDF
414.67 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/586224
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 40
social impact